Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 20/20 | 0.70 |
| ▸ | CXCR2 | P25025 | 20/20 | 0.70 |
| ▸ | CCR7 | P32248 | 1/20 | 0.67 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.58 |
| ▸ | CCR4 | P51679 | 1/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207018 | 0.88 | CXCR1 (0.65) | CXCR1CXCR2CCR7CXCR3CCR4 | |
| SCHEMBL12262779 | 0.84 | CXCR1 (0.93) | CXCR1CXCR2CCR7CXCR3CCR4 | |
| SCHEMBL13208127 | 0.83 | CXCR1 (1.00) | CXCR1CXCR2CCR7 | |
| SCHEMBL13208150 | 0.83 | CXCR2 (1.00) | CXCR1CXCR2CCR7 | |
| SCHEMBL13208128 | 0.82 | CXCR2 (1.00) | CXCR1CXCR2CCR7CCR6 | |
| SCHEMBL13208132 | 0.82 | CXCR1 (1.00) | CXCR1CXCR2CCR7 | |
| SCHEMBL13208164 | 0.81 | CXCR1 (1.00) | CXCR1CXCR2CCR7 | |
| SCHEMBL13227438 | 0.81 | CXCR1 (1.00) | CXCR1CXCR2CCR7 | |
| SCHEMBL12262746 | 0.80 | CXCR2 (1.00) | CXCR1CXCR2CCR7CXCR3CCR4 | |
| SCHEMBL13208175 | 0.79 | CXCR2 (0.67) | CXCR1CXCR2CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | CXCR1 4/4885CXCR2 6/4885CCR7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.